BioSig Technologies (NASDAQ:BSGM) initiated with Buy rating and $9 (75% upside) price target at Roth Capital.
Amgen (NASDAQ:AMGN)
upgraded to Outperform with a $255 (29% upside) price target at Raymond
James citing promise of omecamtiv, AMG 510 and tezepelumab.
Cerner (NASDAQ:CERN) upgraded to Outperform with a $79 price target at Cowen and Company. Shares up 1% premarket.
Galapagos NV (NASDAQ:GLPG) upgraded to Buy with a $232 (27% upside) price target at Jefferies. Shares up 4% premarket.
Nektar Therapeutics (NASDAQ:NKTR) upgraded to Neutral with a $20 (16% upside) price target at Goldman Sachs. Shares up 2% premarket.
Stericycle (NASDAQ:SRCL) upgraded to Outperform with a $75 (79% upside) price target at Baird.
Medical Properties Trust (NYSE:MPW) downgraded to Neutral with a $19 (7% upside) price target at Mizuho Securities. Shares down 2% premarket.
Smith & Nephew (NYSE:SNN) downgraded to Market Perform at Bernstein. Shares up 2% premarket.
Syneos Health (NASDAQ:SYNH) downgraded to Neutral with a $45 (8% upside) price target at Goldman.
Welltower (NYSE:WELL) downgraded to In Line with a $52 (5% upside) price target at Evercore ISI.
https://seekingalpha.com/news/3556223-raymond-james-likes-amgen-in-premarket-analyst-action
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.